The Acuvue Abiliti Overnight Therapeutic Lenses, produced by Jacksonville-based Johnson & Johnson Vision, temporarily reshapes the cornea to reduce the rate of axial elongation.
The Food and Drug Administration has approved the first overnight orthokeratology contact lenses that manage myopia, also known as nearsightedness.
The Acuvue Abiliti Overnight Therapeutic Lenses, produced by Jacksonville-based Johnson & Johnson Vision, temporarily reshapes a patient’s cornea to reduce the rate of axial elongation.
Myopia worsens when there is axial elongation in a person’s eyes, or when their eyeball’s length grows.
A research study found orthokeratology lenses reduced the axial elongation in myopic children’s eyes an average of 0.28 mm over a two-year period.